作者: Jian Tong , Xiaoni Zhang , Hongyue Qu , Qing Yang , Jingxian Duan
DOI: 10.1200/JCO.2020.38.15_SUPPL.E13683
关键词: Cancer research 、 In patient 、 Medicine 、 Positive correlation 、 Non small cell 、 Biomarker (medicine) 、 Mutation (genetic algorithm) 、 Lung cancer 、 Colorectal cancer 、 Immunotherapy
摘要: e13683Background: Tumor mutation burden (TMB) is reported to be a biomarker for predicting immunotherapy responses in patients with non–small cell lung cancer (NSCLC). To provide more accurate ca...